

Correction: *Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy*

Simister PC, Border EC, Vieira JF, *et al.* Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy. *J Immunother Cancer* 2022;10:e004600. doi: 10.1136/jitc-2022-004600.

This article has been corrected since it was first published online. There was a misidentification of the engineered residue; instead of bCDR2 residue E53 engineered it should have been bCDR1 E31. This has now been corrected throughout the article.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e004600corr1. doi:10.1136/jitc-2022-004600corr1

